您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 心血管系统药物->抗心绞痛药物
处方药:处方药
包装规格: 360毫克/胶囊 30胶囊/瓶
计价单位:
  点击放大  
生产厂家中文参考译名:
VALEANT INTL
生产厂家英文名:
VALEANT INTL
该药品相关信息网址1:
www.drugs.com/tiazac.html
该药品相关信息网址2:
www.rxlist.com/tiazac-drug.htm
该药品相关信息网址3:
http://www.medicinenet.com/diltiazem/article.htm
原产地英文商品名:
TIAZAC SA CAPSULE 360mg/cap 30caps/bottle
原产地英文药品名:
DILTIAZEM HCL
中文参考商品译名:
TIAZAC SA胶囊剂 360毫克/胶囊 30胶囊/瓶
中文参考药品译名:
盐酸地尔硫卓
原产地国家批准上市年份:
1995/09/11
英文适应病症1:
Angina
英文适应病症2:
Hypertension
英文适应病症3:
Arrhythmia
临床试验期:
完成
中文适应病症参考翻译1:
心绞痛
中文适应病症参考翻译2:
高血压
中文适应病症参考翻译3:
心律失常
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20125700203228.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文盐酸地尔硫卓处方资料(仅供参考)

盐酸地尔硫卓[diltiazem hydrochloride]相关信息
适应症:
参见用法用量。

成人常用量
口服
心绞痛 初始剂量:60 mg,3次/天,如需要可用至480 mg/天。
高血压 初始剂量: 60-120 mg bid。最大剂量:360 mg/天。静脉给药
心律失常 初始量:250 mcg/kg,必要时,15分钟后可再次给予350 mcg/kg。

服药与进食:服药不受进食影响 (缓释制剂因品牌而异。参见药品说明书。)
 
药物过量:万一药物过量应采取的措施,请查看 盐酸地尔硫卓[diltiazem hydrochloride]药物过量
禁忌 禁用于病态窦房结综合征、Ⅱ或Ⅲ度房室传导阻滞、卟啉病、重度充血性心力衰竭、明显心动过缓患者以及孕妇和哺乳期妇女。

注意事项:慎用于以下情况:老年人,肝脏或肾脏功能不全、左室功能不全、房室传导阻滞、糖尿病和低血压患者。不可长期应用,避免突然停药。病窦综合征、既往有房室传导阻滞和心动过缓及正在服用β-受体阻断剂或洋地黄的患者,有出现房室传导阻滞、心动过缓、心搏停止或窦性停搏的风险。

不良反应:头痛、踝关节水肿、低血压、头晕、疲劳、面红、恶心、胃肠不适、牙龈增生、皮疹、多形性红斑、剥脱性皮炎、光过敏、肝炎。
严重不良反应: 房室传导阻滞,心动过缓,心搏停止,窦性停搏。

药物相互作用:本药可增加血清茶碱水平。西咪替丁可导致本药的血浆浓度升高。本药可增加环孢素的血药水平。
严重药物相互作用: 本药可增加血清茶碱水平。西咪替丁可导致本药的血浆浓度升高。本药可增加环孢素的血药水平。

FDA妊娠分级      
C级: 动物研究证明药物对胎儿有危害性(致畸或胚胎死亡等),或尚无设对照的妊娠妇女研究,或尚未对妊娠妇女及动物进行研究。本类药物只有在权衡对孕妇的益处大于对胎儿的危害之后,方可使用。 

MIMS药物分类:抗心绞痛药 (Anti-Anginal Drugs) / 钙拮抗药 (Calcium Antagonists)

ATC编码:C08DB01 

GENERIC NAME: diltiazem

BRAND NAMES: Cardizem, Dilacor, Tiazac and several others

DRUG CLASS AND MECHANISM: Diltiazem is a drug that is used for treating heart pain (angina), high blood pressure, and abnormal heart rhythms. It belongs to a class of drugs called calcium channel blockers (CCBs), which includes amlodipine (Norvasc), verapamil (Calan, Isoptin), nifedipine (Adalat, Procardia) as well as others. CCBs block the entry of calcium into muscle cells that make up the heart and that surround the arteries. It is the entry of calcium into these cells that causes the cells to contract, allowing the heart to pump blood, and the arteries to narrow. By blocking the entry of calcium, diltiazem decreases the force of contraction of the heart and its rate of contraction. It also relaxes the muscles surrounding the arteries, allowing the arteries to widen (dilate). In order to pump blood, the heart needs oxygen. The harder the heart works, the more oxygen it requires. Angina occurs when the supply of oxygen to the heart is inadequate for the amount of work the heart must do. By dilating arteries, diltiazem reduces the pressure in the arteries into which the heart must pump blood, and, as a result, the heart needs to work less and requires less oxygen. By reducing the heart's need for oxygen, diltiazem relieves or prevents angina. Dilation of the arteries also reduces blood pressure. The FDA approved diltiazem in 1982.

PRESCRIPTION: Yes

GENERIC AVAILABLE: Yes

PREPARATIONS: Tablets (immediate release): 30, 60, 90, and 120 mg. Tablets (extended release): 120, 180, 240, 300, 360, 420 mg. Capsules (extended release): 60, 90, 120, 180, 240, 300, 360, 420 mg. Injection: 5 mg/ml. Powder for injection: 25 mg.

STORAGE: Tablets, capsules and powder for injection should be stored at room temperature, 15-30 C (59-86 F). Solution for injection should be stored at 2-8 C (36-46 F).

PRESCRIBED FOR: Diltiazem is used for treating heart pain (angina), high blood pressure, and abnormal heart rhythms such as atrial fibrillation, atrial flutter and paroxysmal supraventricular tachycardia.

DOSING: Adult oral doses range between 120 and 480 mg daily. Immediate release tablets are administered up to 4 times a day. Extended release formulations are administered once daily at approximately the same time each day and should not be crushed or chewed.

DRUG INTERACTIONS: Administration of diltiazem with digoxin (Lanoxin) can increase digoxin blood levels. Therefore, blood levels of digoxin usually are monitored to avoid toxicity from digoxin. Similarly, concurrent administration of diltiazem with an anti-seizure medication, carbamazepine (Tegretol), can increase blood levels of the seizure medication, and occasionally lead to toxicity. Diltiazem increases blood levels of lovastatin (Mevacor), atorvastatin (Lipitor) and simvastatin (Zocor), possibly increasing the risk of adverse effects. Diltiazem may increase blood levels of buspirone (Buspar), midazolam (Versed), triazolam (Halcion) and diazepam (Valium) by reducing their breakdown and elimination from the body by the liver. This can lead to toxicity from these drugs. Rifampin (Rifamate, Rifadin, Rimactane) reduces the effect of diltiazem by reducing its levels in blood to undetectable levels.

PREGNANCY: There are no adequate studies of diltiazem in pregnant women.

NURSING MOTHERS: Diltiazem is excreted in breast-milk. To avoid adverse effects in the infant, diltiazem should not be taken while nursing.

SIDE EFFECTS: Side effects include constipation, nausea, headache, rash, edema (swelling of the legs with fluid), low blood pressure, drowsiness, and dizziness. Liver dysfunction and overgrowth of the gums also may occur. Diltiazem can cause mildly abnormal liver tests that usually return to normal with discontinuation of the medication. When diltiazem is given to individuals with heart failure, symptoms of heart failure may worsen because these drugs reduce the ability of the heart to pump blood. Like other drugs for high blood pressure, diltiazem is associated with sexual dysfunction.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20125700203228.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2012-5-7
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com